Importantly, we found that concurrent continuous targeting of BRD4 and CDK9 significantly attenuated proliferation of DLBCL cells compared to either experimental compound alone (Fig. 4B). The gene discussed is BRD4; the disease is diffuse large B-cell lymphoma.